I. Veze

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

P. Libby, P. Pais, J. Varigos, 2017, The Lancet.

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

R. Collins, S. Cosgrove, P. Libby, 2017, The Lancet.

Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)

P. Ponikowski, S. Solomon, M. Pfeffer, 2013, European journal of heart failure.

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

P. Libby, P. Pais, J. Varigos, 2017, The Lancet.